Compare JUBILANT LIFE SCIENCES with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

JUBILANT LIFE SCIENCES vs GLENMARK PHARMA - Comparison Results

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    JUBILANT LIFE SCIENCES GLENMARK PHARMA JUBILANT LIFE SCIENCES/
GLENMARK PHARMA
 
P/E (TTM) x 16.0 15.4 104.0% View Chart
P/BV x 2.0 1.8 113.4% View Chart
Dividend Yield % 0.7 0.6 130.6%  

Financials

 JUBILANT LIFE SCIENCES   GLENMARK PHARMA
EQUITY SHARE DATA
    JUBILANT LIFE SCIENCES
Mar-19
GLENMARK PHARMA
Mar-19
JUBILANT LIFE SCIENCES/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs898712 126.2%   
Low Rs618484 127.7%   
Sales per share (Unadj.) Rs572.0349.6 163.6%  
Earnings per share (Unadj.) Rs36.232.8 110.5%  
Cash flow per share (Unadj.) Rs59.544.3 134.2%  
Dividends per share (Unadj.) Rs4.502.00 225.0%  
Dividend yield (eoy) %0.60.3 177.4%  
Book value per share (Unadj.) Rs301.9198.6 152.0%  
Shares outstanding (eoy) m159.28282.17 56.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.31.7 77.5%   
Avg P/E ratio x20.918.2 114.7%  
P/CF ratio (eoy) x12.713.5 94.5%  
Price / Book Value ratio x2.53.0 83.4%  
Dividend payout %12.46.1 203.6%   
Avg Mkt Cap Rs m120,694168,625 71.6%   
No. of employees `0002.412.0 19.9%   
Total wages/salary Rs m19,26020,561 93.7%   
Avg. sales/employee Rs Th38,120.68,196.0 465.1%   
Avg. wages/employee Rs Th8,058.41,708.1 471.8%   
Avg. net profit/employee Rs Th2,414.3768.5 314.2%   
INCOME DATA
Net Sales Rs m91,10898,655 92.4%  
Other income Rs m3572,081 17.2%   
Total revenues Rs m91,466100,736 90.8%   
Gross profit Rs m17,39015,858 109.7%  
Depreciation Rs m3,7093,259 113.8%   
Interest Rs m2,1983,346 65.7%   
Profit before tax Rs m11,84011,335 104.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-2,8021,672 -167.6%   
Tax Rs m3,2683,756 87.0%   
Profit after tax Rs m5,7709,250 62.4%  
Gross profit margin %19.116.1 118.7%  
Effective tax rate %27.633.1 83.3%   
Net profit margin %6.39.4 67.5%  
BALANCE SHEET DATA
Current assets Rs m45,84866,968 68.5%   
Current liabilities Rs m20,89740,211 52.0%   
Net working cap to sales %27.427.1 101.0%  
Current ratio x2.21.7 131.7%  
Inventory Days Days5783 68.2%  
Debtors Days Days5181 62.7%  
Net fixed assets Rs m65,49833,322 196.6%   
Share capital Rs m159282 56.4%   
"Free" reserves Rs m47,93055,770 85.9%   
Net worth Rs m48,08956,052 85.8%   
Long term debt Rs m42,42935,738 118.7%   
Total assets Rs m114,685132,888 86.3%  
Interest coverage x6.44.4 145.6%   
Debt to equity ratio x0.90.6 138.4%  
Sales to assets ratio x0.80.7 107.0%   
Return on assets %6.99.5 73.3%  
Return on equity %12.016.5 72.7%  
Return on capital %12.417.8 69.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m12,42262,998 19.7%   
Fx outflow Rs m17,22722,859 75.4%   
Net fx Rs m-4,80540,140 -12.0%   
CASH FLOW
From Operations Rs m11,21513,242 84.7%  
From Investments Rs m-10,118-6,990 144.8%  
From Financial Activity Rs m6,574-7,387 -89.0%  
Net Cashflow Rs m7,612-2,971 -256.2%  

Share Holding

Indian Promoters % 45.6 48.3 94.4%  
Foreign collaborators % 3.5 0.0 -  
Indian inst/Mut Fund % 8.7 6.9 126.1%  
FIIs % 21.2 34.4 61.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.1 10.5 201.0%  
Shareholders   23,815 56,727 42.0%  
Pledged promoter(s) holding % 15.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare JUBILANT LIFE SCIENCES With:   ORCHID PHARMA LTD  WYETH LTD  ABBOTT INDIA  ALEMBIC LTD  CIPLA  

Compare JUBILANT LIFE SCIENCES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

December Quarter Results, Upcoming IPOs, and Top Stocks in Action Today(Pre-Open)

On Monday, Indian share markets witnessed selling pressure most of the day and ended deep in the red. The BSE Sensex closed lower by 416 points to end the day at 41,529.

Related Views on News

JUBILANT LIFE SCIENCES Announces Quarterly Results (2QFY20); Net Profit Up 18.9% (Quarterly Result Update)

Oct 31, 2019 | Updated on Oct 31, 2019

For the quarter ended September 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (up 18.9% YoY). Sales on the other hand came in at Rs 23 bn (down 0.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of JUBILANT LIFE SCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of JUBILANT LIFE SCIENCES. Also includes updates on the valuation of JUBILANT LIFE SCIENCES.

GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 53.1% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, GLENMARK PHARMA has posted a net profit of Rs 1 bn (down 53.1% YoY). Sales on the other hand came in at Rs 23 bn (up 7.3% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (1QFY20); Net Profit Down 7.7% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (down 7.7% YoY). Sales on the other hand came in at Rs 22 bn (up 5.0% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

More Views on News

Most Popular

My Latest Stock Recommendation(Fast Profits Daily)

Jan 10, 2020

The story behind my latest stock recommendation and an important announcement.

Saffron Curtain = Hindutva Rate of Growth?(The Honest Truth)

Jan 8, 2020

Will the Indian economy revert to a sub-3% growth rate?

Bet on These Smallcap Stocks for Success in 2020(Profit Hunter)

Jan 14, 2020

The smallcap rebound finally seems to here... Make sure you aren't too late to make the most of the biggest wealth making opportunity in a decade.

Your Safe Income Options for 2020(Fast Profits Daily)

Jan 9, 2020

What are you safest investing options in 2020 when interest rates fall.

Guess Which Stocks Are Rising at Double the Speed of Sensex(Profit Hunter)

Jan 15, 2020

These stocks can move twice as fast as the Sensex - to take advantage of their money multiplying power get in now as the rally is still just taking shape.. read more to not miss out.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get our special report, Secret to Increasing Your Trading Profits Today Now!
We will never sell or rent your email id.
Please read our Terms

JUBILANT LIFE SCIENCES SHARE PRICE


Jan 20, 2020 (Close)

TRACK JUBILANT LIFE SCIENCES

  • Track your investment in JUBILANT LIFE SCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON JUBILANT LIFE SCIENCES

JUBILANT LIFE SCIENCES 5-YR ANALYSIS

COMPARE JUBILANT LIFE SCIENCES WITH

MARKET STATS